Aviandr is a new original drug for treating anxiety ; Авиандр – новый оригинальный препарат для терапии тревожных расстройств

Συγγραφείς: V. A. Parfenov, В. А. Парфенов

Συνεισφορές: Publication of this article has been supported by Sotex PharmFirma, Статья опубликована при поддержке компании ЗАО «ФармФирма «Сотекс»

Πηγή: Neurology, Neuropsychiatry, Psychosomatics; Vol 16, No 4 (2024); 98-102 ; Неврология, нейропсихиатрия, психосоматика; Vol 16, No 4 (2024); 98-102 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2024-4

Θεματικοί όροι: селективные ингибиторы обратного захвата серотонина и норадреналина, generalized anxiety disorder, Aviandr, selective serotonin reuptake inhibitors, selective serotonin and norepinephrine reuptake inhibitors, генерализованное тревожное расстройство, Авиандр, селективные ингибиторы обратного захвата серотонина

Περιγραφή αρχείου: application/pdf

Relation: https://nnp.ima-press.net/nnp/article/view/2339/1708; Vos T, Abajobir AA, Abbafati C, et al; GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017 Sep 16;390(10100):1211-59. doi:10.1016/S0140-6736(17)32154-2. Erratum in: Lancet. 2017 Oct 28;390(10106):e38. doi:10.1016/S0140-6736(17)32647-8; Lamers F, van Oppen P, Comijs HC, et al. Comorbidity patterns of anxiety and depressive disorders in a large cohort study: the Netherlands Study of Depression and Anxiety (NESDA). J Clin Psychiatry. 2011 Mar;72(3):341-8. doi:10.4088/JCP.10m06176blu. Epub 2011 Jan 25.; Momen NC, Plana-Ripoll O, Agerbo E, et al. Association between Mental Disorders and Subsequent Medical Conditions. N Engl J Med. 2020 Apr 30;382(18):1721-31. doi:10.1056/NEJMoa1915784; Meier SM, Mattheisen M, Mors O, et al. Increased mortality among people with anxiety disorders: total population study. Br J Psychiatry. 2016 Sep;209(3):216-21. doi:10.1192/bjp.bp.115.171975. Epub 2016 Jul 7.; Alonso J, Liu Z, Evans-Lacko S, et al; WHO World Mental Health Survey Collaborators. Treatment gap for anxiety disorders is global: Results of the World Mental Health Surveys in 21 countries. Depress Anxiety. 2018 Mar;35(3):195-208. doi:10.1002/da.22711. Epub 2018 Jan 22.; Bandelow B, Reitt M, Röver C, et al. Efficacy of treatments for anxiety disorders: a meta-analysis. Int Clin Psychopharmacol. 2015 Jul;30(4):183-92. doi:10.1097/YIC.0000000000000078; Windle E, Tee H, Sabitova A, et al. Association of Patient Treatment Preference With Dropout and Clinical Outcomes in Adult Psychosocial Mental Health Interventions : A Systematic Review and Meta-analysis. JAMA Psychiatry. 2020 Mar 1;77(3):294-302. doi:10.1001/jamapsychiatry.2019.3750; Olthuis JV, Watt MC, Bailey K, et al. Therapist-supported Internet cognitive behavioural therapy for anxiety disorders in adults. Cochrane Database Syst Rev. 2016 Mar 12;3(3):CD011565. doi:10.1002/14651858.CD011565.pub2; Hoge EA, Bui E, Mete M, et al. Mindfulness-Based Stress Reduction vs Escitalopram for the Treatment of Adults With Anxiety Disorders: A Randomized Clinical Trial. JAMA Psychiatry. 2023 Jan 1;80(1):13-21. doi:10.1001/jamapsychiatry.2022.3679; Papola D, Miguel C, Mazzaglia M, et al. Psychotherapies for Generalized Anxiety Disorder in Adults : A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials. JAMA Psychiatry. 2024 Mar 1;81(3):250-9. doi:10.1001/jamapsychiatry.2023.3971. Erratum in: JAMA Psychiatry. 2024 Mar 1;81(3):320. doi:10.1001/jamapsychiatry.2023.5480; Bouchard S, Dugas MJ, Belleville G, et al. A Multisite Non-Inferiority Randomized Controlled Trial of the Efficacy of Cognitive-Behavior Therapy for Generalized Anxiety Disorder Delivered by Videoconference. J Clin Med. 2022 Oct 7;11(19):5924. doi:10.3390/jcm11195924; Slee A, Nazareth I, Bondaronek P, et al. Pharmacological treatments for generalised anxiety disorder : a systematic review and network meta-analysis. Lancet. 2019 Feb 23;393(10173):768-77. doi:10.1016/S0140-6736(18)31793-8. Epub 2019 Jan 31. Erratum in: Lancet. 2019 Apr 27;393(10182):1698. doi:10.1016/S0140-6736(19)30857-8; De Vries YA, Roest AM, Burgerhof JGM, de Jonge P. Initial severity and antidepressant efficacy for anxiety disorders, obsessive-compulsive disorder, and posttraumatic stress disorder: An individual patient data meta-analysis. Depress Anxiety. 2018 Jun;35(6):515-22. doi:10.1002/da.22737. Epub 2018 Apr 16.; Breilmann J, Girlanda F, Guaiana G, et al. Benzodiazepines versus placebo for panic disorder in adults. Cochrane Database Syst Rev. 2019 Mar 28;3(3):CD010677. doi:10.1002/14651858.CD010677.pub2; Ivachtchenko AV, Lavrovsky Y, Okun I. AVN-101: A Multi-Target Drug Candidate for the Treatment of CNS Disorders. J Alzheimers Dis. 2016 May 25;53(2):583-620. doi:10.3233/JAD-151146; Ivashchenko AA, Morozova MA, Vostokova NV, et al. Safety and efficacy of aviandr in patients with generalized anxiety disorder: A multicenter, randomized, double-blind, placebo-controlled, dose-finding, pilot study. J Psychiatr Res. 2021 Nov;143:436-44. doi:10.1016/j.jpsychires.2021.10.008. Epub 2021 Oct 11.; Pollack MH, Zaninelli R, Goddard A, et al. Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial. J Clin Psychiatry. 2001 May;62(5):350-7. doi:10.4088/jcp.v62n0508. Erratum in: J Clin Psychiatry. 2001 Aug;62(8):658.; Baldwin DS, den Boer JA, Lyndon G, et al. Efficacy and safety of pregabalin in generalised anxiety disorder A critical review of the literature. J Psychopharmacol. 2015 Oct;29(10):1047-60. doi:10.1177/0269881115598411. Epub 2015 Aug 10.

Διαθεσιμότητα: https://nnp.ima-press.net/nnp/article/view/2339
https://doi.org/10.14412/2074-2711-2024-4-98-102

The use of antidepressants in neurological practice ; Применение антидепрессантов в неврологической практике

Συγγραφείς: V. A. Parfenov, В. А. Парфенов

Πηγή: Neurology, Neuropsychiatry, Psychosomatics; Vol 15, No 2 (2023); 4-9 ; Неврология, нейропсихиатрия, психосоматика; Vol 15, No 2 (2023); 4-9 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2023-2

Θεματικοί όροι: хроническая мигрень, selective serotonin reuptake inhibitors, selective serotonin and norepinephrine reuptake inhibitors, tricyclic antidepressants, stroke, Alzheimer's disease, depression with cognitive impairment, Parkinson's disease, multiple sclerosis, chronic back pain, chronic migraine, селективные ингибиторы обратного захвата серотонина, селективные ингибиторы обратного захвата серотонина и норадреналина, трициклические антидепрессанты, инсульт, болезнь Альцгеймера, депрессия с когнитивными нарушениями, болезнь Паркинсона, рассеянный склероз, хроническая боль в спине

Περιγραφή αρχείου: application/pdf

Relation: https://nnp.ima-press.net/nnp/article/view/1987/1506; Liu G, Yang X, Xue T, et al. Is Fluoxetine Good for Subacute Stroke? A Meta-Analysis Evidenced From Randomized Controlled Trials. Front Neurol. 2021 Mar 22;12:633781. doi:10.3389/fneur.2021.633781; Романов ДВ, Петелин ДС, Волель БА. Депрессии в неврологической практике. Медицинский совет. 2018;(1):38-45. doi:10.21518/2079-701X-2018-1-38-45.; Мосолов СН. Клиническое применение современных антидепрессантов. Санкт-Петербург: Медицинское информационное агентство; 1995. 568 с.; Elzib H, Pawloski J, Ding Y, Asmaro K. Antidepressant pharmacotherapy and poststroke motor rehabilitation: A review of neurophysiologic mechanisms and clinical relevance. Brain Circ. 2019 Apr-Jun;5(2):62-7. doi:10.4103/bc.bc_3_19. Epub 2019 Jun 27.; Chollet F, Tardy J, Albucher JF, et al. Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial. Lancet Neurol. 2011 Feb;10(2):123-30. doi:10.1016/S1474-4422(10)70314-8. Epub 2011 Jan 7. Erratum in: Lancet Neurol. 2011 Mar;10(3):205.; Savadi Oskouie D, Sharifipour E, Sadeghi Bazargani H, et al. Efficacy of Citalopram on Acute Ischemic Stroke Outcome: A Randomized Clinical Trial. Neurorehabil Neural Repair. 2017 Jul;31(7):638-47. doi:10.1177/1545968317704902. Epub 2017 Apr 28.; FOCUS Trial Collaboration. Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial. Lancet. 2019 Jan 19;393(10168):265-74. doi:10.1016/S0140-6736(18)32823-X. Epub 2018 Dec 5.; Kalbouneh HM, Toubasi AA, Albustanji FH, et al. Safety and Efficacy of SSRIs in Improving Poststroke Recovery: A Systematic Review and Meta-Analysis. J Am Heart Assoc. 2022 Jul 5;11(13):e025868. doi:10.1161/JAHA.122.025868. Epub 2022 Jun 22.; D'Anci KE, Uhl S, Oristaglio J, et al. Treatments for Poststroke Motor Deficits and Mood Disorders: A Systematic Review for the 2019 U.S. Department of Veterans Affairs and U.S. Department of Defense Guidelines for Stroke Rehabilitation. Ann Intern Med. 2019 Dec 17;171(12):906-15. doi:10.7326/M19-2414. Epub 2019 Nov 19.; Galts CPC, Bettio LEB, Jewett DC, et al. Depression in neurodegenerative diseases: Common mechanisms and current treatment options. Neurosci Biobehav Rev. 2019 Jul;102:56-84. doi:10.1016/j.neubiorev.2019.04.002. Epub 2019 Apr 15.; Weintraub D, Rosenberg PB, Drye LT, et al; DIADS-2 Research Group. Sertraline for the treatment of depression in Alzheimer disease: week-24 outcomes. Am J Geriatr Psychiatry. 2010 Apr;18(4):332-40. doi:10.1097/JGP.0b013e3181cc0333; Cumbo E, Cumbo S, Torregrossa S, Migliore D. Treatment Effects of Vortioxetine on Cognitive Functions in Mild Alzheimer's Disease Patients with Depressive Symptoms: A 12 Month, Open-Label, Observational Study. J Prev Alzheimers Dis. 2019;6(3):192-7. doi:10.14283/jpad.2019.24; Takemoto M, Ohta Y, Hishikawa N, et al. The Efficacy of Sertraline, Escitalopram, and Nicergoline in the Treatment of Depression and Apathy in Alzheimer's Disease: The Okayama Depression and Apathy Project (ODAP). J Alzheimers Dis. 2020;76(2):769-72. doi:10.3233/JAD-200247; Elsworthy RJ, Aldred S. Depression in Alzheimer's Disease: An Alternative Role for Selective Serotonin Reuptake Inhibitors? J Alzheimers Dis. 2019;69(3):651-61. doi:10.3233/JAD-180780; Perini G, Cotta Ramusino M, Sinforiani E, et al. Cognitive impairment in depression: recent advances and novel treatments. Neuropsychiatr Dis Treat. 2019 May 10;15:1249-58. doi:10.2147/NDT.S199746; Heser K, Bleckwenn M, Wiese B, et al; AgeCoDe Study Group. Late-Life Depressive Symptoms and Lifetime History of Major Depression: Cognitive Deficits are Largely Due to Incipient Dementia rather than Depression. J Alzheimers Dis. 2016 Aug 1;54(1):185-99. doi:10.3233/JAD-160209; Галкин АС, Васильева СН, Симуткин ГГ и др. Изменение когнитивных функций у пациентов с депрессивными расстройствами в процессе терапии селективными ингибиторами обратного захвата серотонина. Современная терапия психических расстройств. 2021;(1):2-7. doi:10.21265/PSYPH.2021.78.55.001; Connors MH, Quinto L, Brodaty H. Longitudinal outcomes of patients with pseudodementia: a systematic review. Psychol Med. 2019 Apr;49(5):727-37. doi:10.1017/S0033291718002829. Epub 2018 Oct 15.; Goodarzi Z, Mrklas KJ, Roberts DJ, et al. Detecting depression in Parkinson disease: A systematic review and meta-analysis. Neurology. 2016 Jul 26;87(4):426-37. doi:10.1212/WNL.0000000000002898. Epub 2016 Jun 29.; Hsu YT, Liao CC, Chang SN, et al. Increased Risk of Depression in Patients with Parkinson Disease: A Nationwide Cohort Study. Am J Geriatr Psychiatry. 2015 Sep;23(9):934-40. doi:10.1016/j.jagp.2014.10.011. Epub 2014 Nov 6.; Devos D, Dujardin K, Poirot I, et al. Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: a double-blind, randomized, placebo-controlled study. Mov Disord. 2008 Apr 30;23(6):850-7. doi:10.1002/mds.21966; Menza M, Dobkin RD, Marin H, et al. A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology. 2009 Mar 10;72(10):886-92. doi:10.1212/01.wnl.0000336340.89821.b3. Epub 2008 Dec 17.; Richard IH, McDermott MP, Kurlan R, et al; SAD-PD Study Group. A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. Neurology. 2012 Apr 17;78(16):1229-36. doi:10.1212/WNL.0b013e3182516244. Epub 2012 Apr 11.; Bomasang-Layno E, Fadlon I, Murray AN, Himelhoch S. Antidepressive treatments for Parkinson's disease: A systematic review and meta-analysis. Parkinsonism Relat Disord. 2015 Aug;21(8):833-42; discussion 833. doi:10.1016/j.parkreldis.2015.04.018. Epub 2015 May 16.; Orayj K, Almeleebia T, Vigneshwaran E, et al. Trend of recognizing depression symptoms and antidepressants use in newly diagnosed Parkinson's disease: Population-based study. Brain Behav. 2021 Aug;11(8):e2228. doi:10.1002/brb3.2228. Epub 2021 Jun 14.; Jones CD, Motl R, Sandroff BM. Depression in multiple sclerosis: Is one approach for its management enough? Mult Scler Relat Disord. 2021 Jun;51:102904. doi:10.1016/j.msard.2021.102904. Epub 2021 Mar 18.; Fiest KM, Walker JR, Bernstein CN, et al; CIHR Team Defining the Burden and Managing the Effects of Psychiatric Comorbidity in Chronic Immunoinflammatory Disease. Systematic review and meta-analysis of interventions for depression and anxiety in persons with multiple sclerosis. Mult Scler Relat Disord. 2016 Jan;5:12-26. doi:10.1016/j.msard.2015.10.004. Epub 2015 Oct 19.; Mohr DC, Boudewyn AC, Goodkin DE, et al. Comparative outcomes for individual cognitive-behavior therapy, supportive-expressive group psychotherapy, and sertraline for the treatment of depression in multiple sclerosis. J Consult Clin Psychol. 2001 Dec;69(6):942-9.; Ehde DM, Kraft GH, Chwastiak L, et al. Efficacy of paroxetine in treating major depressive disorder in persons with multiple sclerosis. Gen Hosp Psychiatry. 2008 Jan-Feb;30(1):40-8. doi:10.1016/j.genhosppsych.2007.08.002; Stubbs B, Koyanagi A, Thompson T, et al. The epidemiology of back pain and its relationship with depression, psychosis, anxiety, sleep disturbances, and stress sensitivity: Data from 43 low- and middle-income countries. Gen Hosp Psychiatry. 2016 Nov-Dec;43:63-70. doi:10.1016/j.genhosppsych.2016.09.008. Epub 2016 Sep 30.; Gerrits MMJG, van Oppen P, van Marwijk HWJ, et al. Pain and the onset of depressive and anxiety disorders. Pain. 2014 Jan;155(1):53-9. doi:10.1016/j.pain.2013.09.005. Epub 2013 Sep 6.; Hung CI, Liu CY, Fu TS. Depression: An important factor associated with disability among patients with chronic low back pain. Int J Psychiatry Med. 2015;49(3):187-98. doi:10.1177/0091217415573937. Epub 2015 Apr 30.; Kolber MR, Ton J, Thomas B, et al. PEER systematic review of randomized controlled trials: Management of chronic low back pain in primary care. Can Fam Physician. 2021 Jan;67(1):e20-e30. doi:10.46747/cfp.6701e20; Urquhart DM, Wluka AE, van Tulder M, et al. Efficacy of Low-Dose Amitriptyline for Chronic Low Back Pain: A Randomized Clinical Trial. JAMA Intern Med. 2018 Nov 1;178(11):1474-81. doi:10.1001/jamainternmed.2018.4222. Erratum in: JAMA Intern Med. 2019 Mar 1;179(3):457.; Парфенов ВА, Исайкин АИ. Боли в поясничной области. Москва; 2018.; Amiri S, Behnezhad S, Azad E. Migraine headache and depression in adults: a systematic review and meta-analysis. Neuropsychiatr. 2019 Sep;33(3):131-40. doi:10.1007/s40211-018-0299-5. Epub 2019 Jan 21.; Asif N, Patel A, Vedantam D, et al. Migraine With Comorbid Depression: Pathogenesis, Clinical Implications, and Treatment. Cureus. 2022 Jun 16;14(6):e25998. doi:10.7759/cureus.25998; Rampello L, Alvano A, Chiechio S, et al. Evaluation of the prophylactic efficacy of amitriptyline and citalopram, alone or in combination, in patients with comorbidity of depression, migraine, and tension-type headache. Neuropsychobiology. 2004;50(4):322-8. doi:10.1159/000080960; MacGregor EA, Frith AA, Hackshaw A. Efficacy, safety, and tolerability of sertraline on depressive symptoms in women with comorbid migraine: an open-label study. J Clin Psychopharmacol. 2011 Jun;31(3):392-3. doi:10.1097/JCP.0b013e3182189d70; Curone M, Tullo V, Savino M, et al. Outcome of patients with chronic migraine with medication overuse and depression after duloxetine: influence of coexisting obsessive compulsive disorder. Neurol Sci. 2013 May;34 Suppl 1:S175-7. doi:10.1007/s10072-013-1376-y; Volpe FM. An 8-week, open-label trial of duloxetine for comorbid major depressive disorder and chronic headache. J Clin Psychiatry. 2008 Sep;69(9):1449-54. doi:10.4088/jcp.v69n0912; Костюкова ЕГ, Мазо ГЭ, Мосолов СН и др. Биполярное аффективное расстройство. Клинические рекомендации. Взрослые. Электронное издание. Минздрав РФ. Москва; 2021. 245 с. Доступно по ссылке: https://cr.minzdrav.gov.ru/recomend/675_1; Мосолов СН, Малин ДИ, Рывкин ПВ, Сычев ДА. Лекарственные взаимодействия препаратов, применяемых в психиатрической практике. Современная терапия психических расстройств. 2019;(S1):2-35. doi:10.21265/PSYPH.2019.50.40828

Διαθεσιμότητα: https://nnp.ima-press.net/nnp/article/view/1987
https://doi.org/10.14412/2074-2711-2023-2-4-9

The efficacy and safety of alternative treatments for menopausal symptoms in light of recent evidence

Συγγραφείς: S. V. Yureneva, L. M. Ilyina

Πηγή: Медицинский совет, Vol 0, Iss XX, Pp 14-19 (2015)

Θεματικοί όροι: дополнительные альтернативные методы лечения, тканеспецифический эстрогеновый комплекс, селективные ингибиторы обратного захвата серотонина и норадреналина, менопаузальные симптомы, фитоэстрогены, menopausal symptoms, additional alternative therapies, phytoestrogens, selective serotonin reuptake inhibitors, selective serotonin-norepinephrine reuptake inhibitors, tissue selective estrogen complex, Medicine

Περιγραφή αρχείου: electronic resource

Relation: https://www.med-sovet.pro/jour/article/view/466; https://doaj.org/toc/2079-701X; https://doaj.org/toc/2658-5790

Σύνδεσμος πρόσβασης: https://doaj.org/article/53c44d14820741de85f550e478a1a9e6

Применение антидепрессантов для лечения хронической боли: фокус на пожилых пациентов

Συγγραφείς: Ушкалова Е.А., Зырянов С.К., Бутранова О.И.

Πηγή: Advances in gerontology = Uspekhi gerontologii

Θεματικοί όροι: tricyclic antidepressants, selective serotonin and norepinephrine reuptake inhibitors, selective serotonin reuptake inhibitors, analgesics, elderly patients, трициклические антидепрессанты, селективные ингибиторы обратного захвата серотонина и норадреналина, селективные ингибиторы обратного захвата серотонина, анальгетики, пациенты пожилого возраста

Relation: https://repository.rudn.ru/records/article/record/96873/

Διαθεσιμότητα: https://repository.rudn.ru/records/article/record/96873/